RingCentral Appoints Vaibhav Agarwal as Chief Financial Officer

BELMONT, Calif.--(BUSINESS WIRE)--Aug 5, 2025--

RingCentral, Inc. (NYSE: RNG), a global leader in AI-powered business communications, today announced that Vaibhav Agarwal has been appointed Chief Financial Officer, effective immediately. Agarwal, who has been with RingCentral since 2016, will succeed Abhey Lamba, who will continue to serve as an Executive Advisor through the end of the year. Agarwal will be responsible for all the company’s financial functions, including financial planning, controllership, tax, treasury, corporate development and investor relations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250805106969/en/

“I want to congratulate Vaibhav Agarwal on his promotion to Chief Financial Officer of RingCentral. With his nine year tenure in prior roles as Chief Accounting Officer, Chief Transformation Officer, and deputy Chief Financial Officer here at RingCentral, Vaibhav has been a key contributor scaling the company from $400 million to a $2.6 billion run-rate business, while meaningfully contributing to our increasing profitability,” said Vlad Shmunis, Founder, Chairman and CEO of RingCentral. “His deep understanding of our business and proven financial leadership sets us up well for our next phase of profitable growth. I also want to thank Abhey Lamba for his contributions and look forward to working with him in his new role as an executive advisor.”

“I’m honored to step into the role of CFO at RingCentral. We have executed well across all key metrics —delivering profitable growth, expanding margins, achieving GAAP profitability, generating record free cash flow and meaningful FCF per share. This provides us with a flexible capital allocation strategy, focused on investing in innovation, paying down debt, reducing share count, and returning capital to shareholders. With a large market opportunity across UCaaS, CCaaS, and our expanding AI portfolio, I’m excited to work with the leadership team to drive the next chapter of success,” said Vaibhav Agarwal, Chief Financial Officer of RingCentral.

About Vaibhav Agarwal

Agarwal is an accomplished finance executive and has been an integral part of RingCentral’s leadership team since 2016, holding prior roles as Chief Accounting Officer, Chief Transformation Officer, and deputy Chief Financial Officer and supporting the Company’s growth to a $2.6 billion run rate business, from approximately $400 million when he joined.

He brings extensive experience in leading corporate and operational finance experience across the technology industry. Prior to RingCentral, he held senior finance roles at Intel Corporation, Altera, Intuitive Surgical, and PricewaterhouseCoopers. Agarwal holds an MBA from the University of Illinois at Urbana-Champaign, is a Chartered Accountant from India, a California CPA (inactive) and has an undergraduate degree in accounting and finance from the University of Delhi.

About RingCentral

RingCentral is a global leader in AI-powered business communications, contact center, conversational intelligence, video and hybrid event solutions. RingCentral empowers businesses with conversation intelligence and unlocks rich customer and employee interactions to provide insights and improved business outcomes. With decades of expertise in reliable and secure cloud communications, RingCentral has earned the trust of hundreds of thousands of customers and millions of users worldwide. Visit ringcentral.com to learn more.

©2025 RingCentral, Inc. All rights reserved. RingCentral and the RingCentral logo are trademarks of RingCentral, Inc.

Vaibhav Agarwal provided by RingCentral

NEWARK, Del.--(BUSINESS WIRE)--Jan 15, 2026--

QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalysis and clinical trials announces the successful implementation of Oracle Argus, a premier pharmacovigilance system designed to support comprehensive safety case management for clinical trials.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115711485/en/

The adoption of the Oracle Argus drug safety platform underscores QPS’s commitment to advancing patient safety, regulatory compliance, and operational excellence across its clients’ clinical drug development programs. Integrating this industry-standard safety platform strengthens QPS’ ability to capture, manage, and report adverse events in accordance with global regulatory requirements.

“Ensuring patient safety and data integrity is at the heart of what we do when conducting clinical trials,” said Derek Grimes, Executive Vice President of QPS. “Oracle Argus provides us with a robust, scalable solution to support the growing needs of our customer’s clinical trial portfolios and the evolving expectations of regulatory authorities worldwide.”

“Oracle Argus provides QPS Holdings, LLC with a trusted, globally recognized drug safety platform that supports compliance with stringent pharmacovigilance standards and regulations, while streamlining end-to-end safety operations and insights at scale,” said Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences. “With our industry-leading solutions, QPS Holdings, LLC can further transform and elevate its safety case management for customers worldwide.”

The deployment of Oracle Argus will enable QPS to:

As the demand for innovative therapies continues to rise, CROs play a critical role in managing both development speed and patient safety. By leveraging the Oracle Argus platform, QPS is well-positioned to deliver on its mission to accelerate pharmaceutical breakthroughs across the globe by delivering custom-built research services.

###

ABOUT QPS HOLDINGS, LLC

QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,200+ employees in the US, Europe, Asia and India. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, PBMC processing, central safety labs, clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, turnkey laboratories, Phase I/II clinical units, and multi-site clinical research services. For more information, visit http://www.qps.com or email info@qps.com.

ABOUT ORACLE ARGUS

Oracle Argus is an industry-leading, trusted solution for processing, analyzing, and reporting adverse event cases originating in pre-market and post-market drugs, biologics, vaccines, devices, and combination products. Oracle has been a Leader in the IDC MarketScape: Worldwide Life Science R&D Pharmacovigilance Technology Solutions and Consulting Services 2025 Vendor Assessment (doc # US53669225, July 2025). To learn more about Oracle’s pharmacovigilance portfolio visit: https://www.oracle.com/life-sciences/safety-solutions/argus-safety-case-management/. Trademarks: Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation.

Derek Grimes, EVP, Global Head of Clinical Research at QPS Holdings, LLC.